L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in
combination with doxorubicin, as well as preliminary anti-tumor activity in patients with
previously treated advanced pancreatic cancer.